

Request for Prior Authorization

Iowa Health Link Hawki

FAX Completed Form To 1 (877) 733-3195 Provider Help Desk

DIRECT ORAL ANTICOAGULANTS

(PLEASE PRINT – ACCURACY IS IMPORTANT) I (844) 236-I464 IA Medicaid Member ID # Patient name DOB Patient address Provider NPI Prescriber name Phone Prescriber address Fax Pharmacy name Address Phone Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. NDC Pharmacy NPI Pharmacy fax

Prior authorization (PA) is not required for preferred direct oral anticoagulants (DOACs). Prior authorization is required for non-preferred DOACs. Requests will be considered for FDA approved dosing and length of therapy for submitted diagnosis. Requests for doses outside of the manufacturer recommended dose will not be considered. Payment will be considered for FDA approved or compendia indications for the requested drug under the following conditions: I) Patient is within the FDA labeled age for indication; and 2) Patient does not have a mechanical heart valve; and 3) Patient does not have active bleeding; and 4) For a diagnosis of atrial fibrillation or stroke prevention, patient has the presence of at least one additional risk factor for stroke, with a CHA₂DS₂-VASc score ≥I; and 5) A recent creatinine clearance (CrCl) is provided; and 6) A recent Child-Pugh score is provided; and 7) Patient's current body weight is provided; and 8) Patient has documentation of a trial and therapy failure at a therapeutic dose with at least two preferred DOACs; and 9) For requests for edoxaban, when prescribed for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), documentation patient has had 5 to 10 days of initial therapy with a parenteral anticoagulant (low molecular weight heparin or unfractionated heparin) is provided. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

<u>Preferred</u>	(no PA required	Non-Preferre	Non-Preferred (PA required)		
☐ Eliquis ☐ Xarelto				☐ Bevyxxa	Savaysa
Pradaxa				Dabigatran	Xarelto Suspension
	Strength	Dosage Instructions		Quantity [Days Supply
Diagnosis:					
Does patie	ent have mechan	ical heart valve?	Yes	☐ No	
Does patie	ent have active b	eeding?	Yes	☐ No	
Patient body weight:				Date obtained:	
Provide recent creatinine clearance (CrCl):				Date obtained:	
Provide recent Child-Pugh score:				Date completed:	

Request for Prior Authorization DIRECT ORAL ANTICOAGULANTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Risk factor based CHA2DS2-VASc Score

Risk Factors

Requests for a diagnosis of atrial fibrillation or stroke prevention:

	Congestive neart failure			
	Hypertension	I		
	Age ≥ 75 years	2		
	Age between 65 and 74 years	Į.		
	Stroke / TIA / TE	2		
	Vascular disease (previous MI, peripheral arterial disease or aortic plaque)	1		
	Diabetes mellitus	ı		
	Female	I		
	T	otal		
Document 2 preferred DOA Preferred DOAC Trial 1: Name	AC trials: /Dose:	Trial Dates:		
Failure reason:				
Preferred DOAC Trial 2: Name	/Dose:	Trial Dates:		
Failure reason:				
Requests for edoxaban (Sava	aysa):			
Provide documentation of 5 to I or unfractionated heparin) for di	0 days of initial therapy with a parenteral iagnosis of DVT or PE:	l anticoagulant (low	molecular weight heparin	
Drug name & dose:		_ Trial dates:		
Medical or contraindication reas	on to override trial requirements:			
Attach lab results and other d	ocumentation as necessary.		_	
Prescriber signature (Must match pr	<u> </u>	Date of subm	ission	
1				

Score

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

PAA-1031 Page 2 of 2